Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 13, No. 3, 2014, pp. 331-338
Bioline Code: pr14048
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 13, No. 3, 2014, pp. 331-338
© Copyright 2014 - Tropical Journal of Pharmaceutical Research
TfR Binding Peptide Screened by Phage Display Technology - Characterization to Target Cancer Cells|
Dai, Xiaoyong; Xiong, Yaoling; Xu, Dandan; Li, Linyan; Su, Zhijian; Zhang, Qihao & Zheng, Qing
Purpose: To screen an hTfR affinity peptide and investigate its activity in vitro.
Methods: hTfR affinity phage clones were screened from 7-mer phage display library, and their binding
ability evaluated by enzyme-linked immunosorbent assay (ELISA). A competitive assay was performed
to discover the peptide BP9 (BP9) binding site on the cells. The inhibitory effect of BP9 on the cells was
determined using thiazolyl blue (MTT) assay. EGFP-BP9 fusion protein was expressed in E. coli, and its
binding and localization on cells were determined by fluorescence microscopy and confocal microscopy,
Results: After three rounds of panning, recovery efficiency was 48-fold higher than that of the first
round. The peptide BP9 sharing 2 identical amino acids to Tf showed high-affinity to hTfR, and
possessed strong proliferation inhibition ratio on different tumour cells of 70 % (HepG2 cells)/77 %
(SMMC-7221 cells) at a concentration of 0.1 mM, and 85 % (HepG2 cells)/81 % (SMMC-7221 cells) at a
concentration of 0.001 mM for 48 h. The recombinant protein EGFP–BP9 could bind to tumour cells and
gain entry via the endocytic pathway.
Conclusion: BP9 can bind to TfR and inhibit the proliferation of the tumour cells over-expressing TfR.
The DNA sequence coding for BP9 was able to target the macromolecule to combine with TfR. BP9
may possess potential applications in cancer therapy.
Peptide; hTfR; Transferrin receptor; Phage display technology; Enhanced green fluorescence protein; Target; Cancer cells
Alternative site location: http://www.tjpr.org